Trinity Biotech PLC (TRIB) Scheduled to Post Earnings on Monday
Trinity Biotech PLC (NASDAQ:TRIB) is scheduled to post its quarterly earnings results on Monday, October 23rd. Analysts expect Trinity Biotech PLC to post earnings of $0.07 per share for the quarter.
Trinity Biotech PLC (NASDAQ:TRIB) last posted its quarterly earnings results on Thursday, July 20th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.03). Trinity Biotech PLC had a negative net margin of 100.45% and a positive return on equity of 5.54%. The business had revenue of $25.45 million during the quarter, compared to analysts’ expectations of $24.83 million. On average, analysts expect Trinity Biotech PLC to post $0.08 EPS for the current fiscal year and $0.17 EPS for the next fiscal year.
Shares of Trinity Biotech PLC (NASDAQ TRIB) opened at 5.26 on Monday. The stock’s market capitalization is $114.92 million. The firm has a 50-day moving average of $5.40 and a 200 day moving average of $5.61. Trinity Biotech PLC has a 12-month low of $5.09 and a 12-month high of $7.40.
An institutional investor recently raised its position in Trinity Biotech PLC stock. State Street Corp raised its holdings in Trinity Biotech PLC (NASDAQ:TRIB) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 37,614 shares of the company’s stock after purchasing an additional 781 shares during the quarter. State Street Corp owned about 0.17% of Trinity Biotech PLC worth $225,000 as of its most recent filing with the SEC. 62.10% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/16/trinity-biotech-plc-trib-scheduled-to-post-earnings-on-monday.html.
Separately, Zacks Investment Research lowered shares of Trinity Biotech PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, September 20th.
Trinity Biotech PLC Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.